Clinical experience of bilastine treatment in patients suffering from allergic diseases



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The results of clinical observation of 60 patients with urticaria (n=30) and perennial allergic rhinitis (n=30) aged from 12 to 61 years old are presented. All patients were treated with bilastine 20 mg once a day during 30 days. The assessment of urticaria activity score (UAS, UAS7), nasal and non nasal symptoms severity score of allergic rhinitis has been performed before, 2 weeks and 4 weeks of the treatment. The majority of patients demonstrated control of disease symptoms. The efficacy and safety of bilastine 20 mg in chronic spontaneous and acute urticaria as well as allergic rhinitis was shown.

Full Text

Restricted Access

About the authors

O G Elisyutina

NRC Institute of Immunology FMBA ofRussia

Email: o.elisyutina@nrcii.ru

E S Fedenko

NRC Institute of Immunology FMBA ofRussia

O V Shtyrbul

NRC Institute of Immunology FMBA ofRussia

E N Zemskaya

NRC Institute of Immunology FMBA ofRussia

A O Litovkina

NRC Institute of Immunology FMBA ofRussia

E V Smolnikov

NRC Institute of Immunology FMBA ofRussia

References

  1. Аллергология. Федеральные клинические рекомендации. Под ред. Хаитова РМ, Ильиной Н.И. К.: ВСИ Медицина. 2012: 520
  2. Козулина ИЕ, Курбачева ОМ, Ильина Н.И. Аллергия сегодня. Анализ новых эпидемиологических данных. Российский Аллергологический Журнал. 2014; (3): 3-10
  3. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт. 1998
  4. Simons FER, Simons KJ. H1-antihistamines: Cuurrent status and future directions. World Allergy Organ J. 2008; 1: 145-155. doi: 10.1097/WOX.0b013e318186fb3a.
  5. Holgate ST, Canonica GW, Simons FE, Taglialatela M., Tharp M., Timmerman H. et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clinical & Experimental Allergy. 2003; 33: 1305-1324. doi: 10.1046/j.1365-2222.2003.01769.x.
  6. Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011; 4: 22-27. doi: 10.1097/WO.0b013e3181f385d9.
  7. Wolthers OD. Bilastine: a new nonsedating oral H1-antihistamine for treatment of allergic rhinoconjunctivitus and urticaria. Biomed Res Int. 2013. doi: 10.1155/2013/626837.
  8. Ridolo E., Montagni M., Bonzano L., Incorvaria C., Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015; 13: 1. doi: 10.1186/s12948-015-0008-x.
  9. Lucero ML, Gonzalo A., Ganza A., Leal N., Soengas I., Ioja E. et al. Interactions of bilastine, a new oral Ні-antihistamine with human transporter systems. Drug Chem Toxicol. 2012; 35: 8-10. doi: 10.3109/01480545.2012.682653.
  10. Sadaba B., Gomez-Guiu A., Azanza JR, Ortega I., Valiente R. Oral availability ofbilastene. Clin Drug Investig. 2013; 33: 375-381. doi: 10.1007/s40261-013-0076-y.
  11. Kuna P., Bachert C., Nowacki Z., van Cauwenberge P., Agache I., Fouquert L. et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009; 39: 338-347. doi: 10.1111/j.1365-2222.2009.03257.x.
  12. Bachert C., Kuna P., Sanquer F., Ivan P., Dimitrov V., Gorina MM et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Bilastine International Working Group. Allergy. 2009; 64: 158-165. doi: 10.1111/j.1398-9995.2008.01813.x.
  13. Sastre J., Mullol J., Valero A., Valiente R. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012; 28: 121-130. doi: 10.1185/03007995.2011.640667.
  14. Yagami A., Furue M., Togawa M., Saito A., Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J. Dermatol. 2017; 44(4): 375-385. doi: 10.1111/1346-8138.13644.
  15. Zuberbier T., Oanta A., Bogacka E., Medina I., Wesel F., Uhl P. et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010; 65: 516-528. doi: 10.1111/j.1398-9995.2009.02217.x.
  16. Tyl B., Kabbaj M., Azzam S., Sologuren A., Valiente R., Reinbolt E. et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concen-tration analysis. J. Clin Pharmacol. 2012; 52: 893-903. doi: 10.1177/0091270011407191.
  17. Garcia-Gea C., Martinez J., Ballester MR, Gich I., Valiente R., Antonijoan RM. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I. clinical trials. Hum Psycho-pharmacol. 2014; 29: 120-132. doi: 10.1002/hup.2378.
  18. Zuberbier T., Aberer W., Asero R., Bindslev-Jensen C., Brzoza Z., Canonica GW et all. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69: 868-887. doi: 10.1002/hup.2378.
  19. Brożek JL, Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J. Allergy Clin Immunol. 2017; 140(4): 950-958. doi: 10.1016/j.jaci.2017.03.050.
  20. Zuberbier T., Aberer W., Asero R., Abdul Latiff AH, Baker D., Ballmer-Weber B. et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018 Jan 15. doi: 10.1111/all.13397.
  21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3): 210-216.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2018



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies